Update on optimal use of lisdexamfetamine in the treatment of ADHD

Vishal Madaan, Venkata Kolli, Durga P Bestha, Manan J ShahDepartment of Psychiatry and Neurobehavioral Sciences, Division of Child and Family Psychiatry, University of Virginia Health System, Charlottesville, VA, USAAbstract: Lisdexamfetamine (LDX) has been a recent addition to the treatment armamen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Madaan V, Kolli V, Bestha DP, Shah MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/66d15f362b1b4855b3041aeb77e69530
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66d15f362b1b4855b3041aeb77e69530
record_format	dspace
spelling	oai:doaj.org-article:66d15f362b1b4855b3041aeb77e695302021-12-02T02:36:48ZUpdate on optimal use of lisdexamfetamine in the treatment of ADHD1176-63281178-2021https://doaj.org/article/66d15f362b1b4855b3041aeb77e695302013-07-01T00:00:00Zhttp://www.dovepress.com/update-on-optimal-use-of-lisdexamfetamine-in-the-treatment-of-adhd-a13737https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Vishal Madaan, Venkata Kolli, Durga P Bestha, Manan J ShahDepartment of Psychiatry and Neurobehavioral Sciences, Division of Child and Family Psychiatry, University of Virginia Health System, Charlottesville, VA, USAAbstract: Lisdexamfetamine (LDX) has been a recent addition to the treatment armamentarium for Attention Deficit Hyperactivity Disorder (ADHD). It is unique among stimulants as it is a prodrug, and has been found to be safe and well-tolerated medication in children older than 6 years, adolescents and adults. It has a smooth onset of action, exerts its action up to 13 hours and may have less rebound symptoms. LDX has proven to be effective in the treatment of ADHD in placebo controlled trials, and improved performance in simulated academic and work environments have been noticed. Both stimulant naïve and stimulant-exposed patients with ADHD appear to benefit from LDX. It has also shown some promise in improving emotional expression and executive function of patients with ADHD. Adverse effects such as decrease in sleep, loss of appetite and others have been reported with LDX use, just as with other stimulant formulations. Since most such studies exclude subjects with preexisting cardiac morbidity, prescribing precautions should be taken with LDX in such subjects, as with any other stimulant. Study subjects on LDX have been reported to have low scores on drug likability scales, even with intravenous use; as a result, LDX may have somewhat less potential for abuse and diversion. There is a need for future studies comparing other long acting stimulants with LDX in ADHD; in fact clinical trials comparing LDX with OROS (osmotic controlled-release oral delivery system) methylphenidate are currently underway. Furthermore, the utility of this medication in other psychiatric disorders and beyond ADHD is being investigated.Keywords: lisdexamfetamine, ADHD, functional impairment, pharmacotherapyMadaan VKolli VBestha DPShah MJDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 977-983 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Madaan V Kolli V Bestha DP Shah MJ Update on optimal use of lisdexamfetamine in the treatment of ADHD
description	Vishal Madaan, Venkata Kolli, Durga P Bestha, Manan J ShahDepartment of Psychiatry and Neurobehavioral Sciences, Division of Child and Family Psychiatry, University of Virginia Health System, Charlottesville, VA, USAAbstract: Lisdexamfetamine (LDX) has been a recent addition to the treatment armamentarium for Attention Deficit Hyperactivity Disorder (ADHD). It is unique among stimulants as it is a prodrug, and has been found to be safe and well-tolerated medication in children older than 6 years, adolescents and adults. It has a smooth onset of action, exerts its action up to 13 hours and may have less rebound symptoms. LDX has proven to be effective in the treatment of ADHD in placebo controlled trials, and improved performance in simulated academic and work environments have been noticed. Both stimulant naïve and stimulant-exposed patients with ADHD appear to benefit from LDX. It has also shown some promise in improving emotional expression and executive function of patients with ADHD. Adverse effects such as decrease in sleep, loss of appetite and others have been reported with LDX use, just as with other stimulant formulations. Since most such studies exclude subjects with preexisting cardiac morbidity, prescribing precautions should be taken with LDX in such subjects, as with any other stimulant. Study subjects on LDX have been reported to have low scores on drug likability scales, even with intravenous use; as a result, LDX may have somewhat less potential for abuse and diversion. There is a need for future studies comparing other long acting stimulants with LDX in ADHD; in fact clinical trials comparing LDX with OROS (osmotic controlled-release oral delivery system) methylphenidate are currently underway. Furthermore, the utility of this medication in other psychiatric disorders and beyond ADHD is being investigated.Keywords: lisdexamfetamine, ADHD, functional impairment, pharmacotherapy
format	article
author	Madaan V Kolli V Bestha DP Shah MJ
author_facet	Madaan V Kolli V Bestha DP Shah MJ
author_sort	Madaan V
title	Update on optimal use of lisdexamfetamine in the treatment of ADHD
title_short	Update on optimal use of lisdexamfetamine in the treatment of ADHD
title_full	Update on optimal use of lisdexamfetamine in the treatment of ADHD
title_fullStr	Update on optimal use of lisdexamfetamine in the treatment of ADHD
title_full_unstemmed	Update on optimal use of lisdexamfetamine in the treatment of ADHD
title_sort	update on optimal use of lisdexamfetamine in the treatment of adhd
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/66d15f362b1b4855b3041aeb77e69530
work_keys_str_mv	AT madaanv updateonoptimaluseoflisdexamfetamineinthetreatmentofadhd AT kolliv updateonoptimaluseoflisdexamfetamineinthetreatmentofadhd AT besthadp updateonoptimaluseoflisdexamfetamineinthetreatmentofadhd AT shahmj updateonoptimaluseoflisdexamfetamineinthetreatmentofadhd
_version_	1718402354454200320

Update on optimal use of lisdexamfetamine in the treatment of ADHD

Ejemplares similares